coplug
    Back to PCN explorer
    PCN reports · Core20PLUS5

    Swagga PCN, Liverpool (LAD) · Health Inequalities Profile

    PCN U57480 · NHS Cheshire and Merseyside Integrated Care Board · 16 GP practices

    Read the report

    This report is generated by Coplug's Healthcare Agent. Log in to ask further questions of it, add the spatial context, or create new enquiries to better understand and improve your Neighbourhood's Health

    01 / 15

    Board summary

    Key figures

    93,532

    Registered population

    59.1% aged 18–64

    21.3%

    Aged 65+

    ICB 19.0% · England 17.9%

    8.5%

    Ethnic minority (non-White)

    3.3% Asian · England 9.6%

    33.8%

    In IMD quintile 1

    ICB 31.9% · England 21.0%

    ~34,815

    Core20 residents (est.)

    Resident basis; registered basis ~31,442 · see page 3

    16,777

    Hypertension register

    +4.26% in 3 yrs · England +5.60%

    1,169

    SMI register

    13.9% of Liverpool (LAD)'s

    2,911

    COPD register

    Reviews +0.97% in 3 yrs

    Forecast to 2030

    18,828

    Hypertension patients, 2030

    +2,051 on today

    68.7%

    QRISK ≥20% on statins, 2030

    +3.17pp over 3 yrs

    5.6%

    Cancer prevalence, 2030

    England 4.5%

    Three things the board should see

    70.5 pp
    Wide practice spread in phone contact ease.

    GPPS phone access spans 70.5 pp across 16 practices, while overall good experience spans 56.0 pp, which may reflect unverified local triage variation.

    63.8%
    Asthma reviews and BP recording trail England.

    Asthma reviews reach 63.8% (England 65.7%, leaving about 2,200 unreviewed) and recent BP readings reach 86.0% (England 90.0%), which may reflect recall gaps.

    +14.6%
    Breast screening and diabetes control outpace England.

    Breast screening coverage rose +14.6% (England +8.4%) to 71.4%, while diabetes HbA1c control without frailty rose +13.8% (England +4.4%).

    Sources & context

    PCN and practice-level primary care data; ICB and provider context on page 8

    Powered by Coplug · Page 1 of 15
    02 / 15

    Population, age and ethnicity

    Adults aged 65+ represent 21.3% of registered patients, exceeding borough and national levels

    SWAGGA PCN serves 93,532 registered patients across its practices. Adults aged 65+ make up 21.3% (19,958 patients), above Liverpool (15.6%), the ICB (19.0%), and England (17.9%). Patients aged 18–64 represent 59.1% and aged 0–17 comprise 19.6%. Census resident estimates indicate 91.5% White ethnicity (Liverpool 84.0%, ICB 93.0%, England 81.1%) and an 8.5% ethnic minority share; registered-patient ethnicity was not captured. Projected list growth is 2.4% to 2030 under an unverified methodology.

    Age profile

    0–1719.6%
    18–6459.1%
    65+21.3%

    65+: ICB 19.0%, England 17.9%

    Ethnicity

    White91.5%
    Asian3.3%
    Mixed3.0%
    Black1.2%
    Other1.1%

    Older people · falls rows are Liverpool (LAD) local-authority (LA) data, not PCN

    MeasureLocalNorth WestEnglandPeriod
    Falls admissions, 65+, per 100,000 (Liverpool LA)3,0352,0711,9582024/25
    Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN)81.4%82.9%81.9%2024/25
    Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN)56.5%56.6%57.4%2024/25
    Falls admissions, 65 to 79, per 100,000 (Liverpool LA)1,6521,0219552024/25
    Falls deaths, all ages, per 100,000 (Liverpool LA)27.518.214.82022‑24
    Sources & context

    Census 2021; Fingertips falls and diabetes. Falls are local-authority data. Ethnic minority = 100% minus White

    Powered by Coplug · Page 2 of 15
    03 / 15

    Deprivation and Core20

    Core20 deprivation averages 33.8% across the PCN but spans 100 pp between practices

    The PCN Core20 share is 33.8%, above England (21.0%) and the ICB (31.9%) but below Liverpool (54.9%), with an average IMD decile of 4.8. Core20 concentration spans 100 pp across practices, from 0.0% at Storrsdale Medical Centre to 100.0% at Netherley Health Centre, while Speke Hc - Dr Thakur holds 5,308 estimated Core20 patients. Weighted practice share is 33.6%. Wide deprivation variation indicates that clinical review priorities and outreach capacity may need tailoring by practice cohort.

    % of patients in IMD quintile 1, by practice

    Dashed line: England 21.0% · right column: Core20 patients, registered basis

    Netherley100.0% · 3,231 patients
    Speke Hc - Dr97.3% · 4,819 patients
    Speke Hc - Dr95.9% · 5,308 patients
    Margaret Thompson85.0% · 5,080 patients
    Garston Family59.0% · 1,939 patients
    Gateacre56.6% · 1,419 patients
    Village48.7% · 2,839 patients
    Gateacre Brow27.0% · 1,736 patients
    Hillfoot Health25.2% · 2,107 patients
    Mather Avenue18.5% · 1,570 patients
    Woolton House6.8% · 610 patients
    Village Medical5.7% · 211 patients
    Grassendale5.2% · 449 patients
    Ash1.9% · 124 patients
    Storrsdale0.0% · 0 patients
    Fulwood Green0.0% · 0 patients
    Sources & context

    Deprivation: Index of Multiple Deprivation, applied to registered patients

    Powered by Coplug · Page 3 of 15
    04 / 15

    PLUS groups and inclusion health

    PLUS groups and inclusion health

    1,169

    SMI register

    1.24% recorded prevalence

    589

    Learning disability register

    0.63% recorded prevalence

    25

    Care homes, 1,099 beds

    In the PCN catchment

    10.3%

    Provide unpaid care

    Liverpool (LAD), Census 2021

    The PCN records 1,169 patients with severe mental illness (1.2%, above England's 1.0%) and 589 with learning disabilities (0.6%, matching England at 0.6%). The catchment includes 25 care homes with 1,099 beds; registered resident numbers were not captured. Separately, Liverpool local authority recorded 35 rough sleepers in an autumn 2025 snapshot and a 10.3% unpaid care rate, ranking 8 of 39 North West local authorities.

    Severe mental illness: physical health checks

    Recorded SMI prevalence is 1.2% (England 1.0%, Liverpool (LAD) 1.4%). Annual checks reached 84.3% for blood pressure (England 83.4%) and 82.4% for BMI (England 82.1%). Published individual checks show strong delivery, though comprehensive checks are not captured.

    Sources & context

    QOF registers; Census 2021 carers; care homes and homelessness as supplied. Carers and homelessness are local-authority data

    Powered by Coplug · Page 4 of 15
    05 / 15

    Clinical focus: hypertension and lipids

    Clinical focus: hypertension and lipids

    16,777

    Hypertension register

    +4.26%

    Register growth, 3 yrs

    Liverpool (LAD) +2.01% · England +5.60%

    +4.40pp

    BP control, under 80

    ≤140/90 · +3.58pp aged 80+

    +2,051

    More patients by 2030

    Forecast 18,828 (19.36%)

    Hypertension case-finding and control

    Recorded hypertension prevalence is 17.8% (16,777 patients), above Liverpool (14.0%), the ICB (16.8%), and England (15.2%). However, recent blood pressure recording reaches 86.0%, trailing Liverpool (87.8%), the ICB (88.3%), and England (90.0%). Blood pressure control to target is 69.4%, below England (70.3%) and Liverpool (69.8%), though above the ICB (69.1%). In patients aged under 80, control to <= 140/90 mmHg is 66.5% (England 67.8%), while for those aged 80 and over, control reaches 81.3% (England 81.2%). Observation periods between the register and list are unconfirmed. Routine blood pressure recording lags national rates despite high recorded prevalence, meaning unmeasured hypertension patients risk delayed treatment optimisation unless recall is prioritised.

    Lipids and statins

    Patients with QRISK >= 20% on lipid-lowering therapy reach 61.8%, trailing the ICB (63.2%), England (63.6%), and Liverpool (65.6%). Statin therapy for diabetes patients aged 40 and over without CVD is 70.1% (England 73.2%, ICB 72.4%). Fewer at-risk cardiovascular patients receive lipid-lowering therapy than benchmark rates imply, highlighting an opportunity to prioritise statin initiation.

    MeasureItemsCost / itemICBEnglandAnnual spend
    Lipid-modifying, 2026176,132£2.00£1.71£1.86£352,264
    Cardiovascular (all), 2025254,180£4.65£4.37£3.33£1,181,937

    For lipid-regulating drugs in 2026, the PCN prescribed 176,132 items at £2.00 per item, above Liverpool (£1.82), England (£1.86), and the ICB (£1.71), spending £24,658 more than at England's unit cost.

    Sources & context

    QOF hypertension register and BP control indicators; prescribing items and cost as supplied

    Powered by Coplug · Page 5 of 15
    06 / 15

    Clinical focus: respiratory, cancer register and children

    Clinical focus: respiratory, cancer register and children

    Respiratory

    +0.14%

    Asthma reviews, PCN 3-yr % change

    +4.44%

    Asthma reviews, England 3-yr % change

    +2.00%

    Asthma prevalence, PCN 3-yr % change

    Recorded prevalence is above England for COPD at 3.1% (England 1.9%, Liverpool (LAD) 3.0%) with 2,911 patients, and asthma at 7.0% (England 6.6%, Liverpool (LAD) 6.1%) with 6,172 patients. Asthma annual reviews reached 63.8%, below England (65.7%) and Liverpool (LAD) (64.3%), with three-year growth (+0.1% vs England +4.4%) leaving about 2,200 unreviewed patients. Asthma prescribing reached 2,411 items per 1000 aged 5-19 (England 1,488).

    Cancer register and children's immunisation

    Cancer prevalence is 4.6% with 4,360 registered patients, above England (3.8%) and Liverpool (LAD) (3.3%). In Q1 2025/26, 6-in-1 coverage at 12 months was 89.3% (England 91.0%). At age 5, an 8.2 pp gap separates MMR dose 1 (89.4%) from dose 2 (81.2%, England 82.8%; cohort 207), below the 95.0% target, while 4-in-1 booster coverage was 82.1%.

    Dashed line: 95% national coverage target · solid tick: England

    6-in-1 at 12 months89.3%

    England 91.0%

    6-in-1 complete primary course at 24 months92.0%

    England 92.2%

    MMR dose 1 at 24 months89.6%

    England 88.3%

    MMR dose 2 at age 581.2%

    England 82.8%

    4-in-1 pre-school booster at age 582.1%

    England 80.9%

    Sources & context

    QOF registers and review indicators; childhood immunisation coverage as supplied

    Powered by Coplug · Page 6 of 15
    07 / 15

    Early cancer diagnosis

    Early cancer diagnosis

    55.5%

    Cheshire and Merseyside ICB, stage 1–2

    55.3%

    England, 2022

    75%

    National ambition by 2028

    ~2,640

    Extra early-stage cases a year to reach the ambition

    Stage 1–2 share by cancer type, 2022Cheshire and Merseyside ICBEnglandNo usable stageStaged cancers
    Lung40.4%33.8%11%2,354
    Breast87.1%85.4%11%2,083
    Prostate52.3%53.2%12%2,037
    Bowel44.9%47.0%16%1,674
    Skin cancer86.9%87.8%21%932

    At ICB level (not PCN level), across NHS Cheshire and Merseyside ICB in 2022, 55.5% of staged cancers were diagnosed at stage 1 or 2 (72.8% known stage), falling 19.5 pp below the 75.0% national ambition, an ICB gap of about 2,640 cases. From 2013 to 2022, ICB early-stage share rose +2.6 pp from 52.8% to 55.5%. At PCN level, SWAGGA PCN recorded cancer prevalence is 4.6% (4,360 patients; England 3.8%). Cervical screening coverage is 70.3% (England 66.8%), but Garston Family Health Centre recorded 60.5% and Netherley Health Centre recorded 61.7%. Supporting early diagnosis requires addressing these practice screening shortfalls.

    Sources & context

    Stage at diagnosis: National Disease Registration Service

    Powered by Coplug · Page 7 of 15
    08 / 15

    Cancer waits, diagnostics and community services

    Cancer waits, diagnostics and community services

    Cancer waits and diagnostics, Jul 2026 (provisional)

    At provider and ICB level (not PCN level), for Mersey and West Lancashire Teaching Hospitals NHS Trust, performance on the 62-day referral to treatment standard was 7.0 pp below the 85.0% standard, while NHS Cheshire and Merseyside Integrated Care Board was 8.8 pp below. On the 28-day faster diagnosis standard, the trust was 2.6 pp below the 75.0% standard, while the ICB was 2.2 pp above it. On the 31-day combined standard, the trust fell 0.5 pp below the 96.0% target and the ICB fell 0.3 pp below. These figures describe wider system performance rather than PCN delivery.

    Pathways within standard (%)Mersey and West LancashireLiverpoolNorth Cheshire and MerseyCheshire and Merseyside ICBEngland
    28-day faster diagnosis (75%)72.3975.4780.2177.2579.32
    31-day treatment (96%)95.4690.5198.1795.7192.50
    62-day referral to treatment (85%)77.9673.2683.6776.2371.16
    Diagnostic waits over 6 weeks (%)Mersey and West LancashireLiverpoolNorth Cheshire and MerseyEngland
    MRI14.046.420.5321.40
    CT13.080.712.329.92
    Echocardiography34.8812.5528.0428.48
    Colonoscopy18.0433.1415.9830.83
    Gastroscopy18.1744.9920.2429.02
    All 15 DM01 tests21.1711.506.3423.14
    Community services activityLiverpool residentsCheshire and Merseyside ICB
    Care contacts127,380541,280
    Referrals15,67597,150
    Patients with a contact24,970146,240

    Community services (residents of Liverpool), Jun 2026 (provisional). At local authority level (not PCN level), adults aged 65 and over accounted for 65.4% of community health service contacts (83,300 of 127,380 borough residents' contacts) in Liverpool in provisional figures for June 2026. These activity data describe borough-wide community services rather than PCN-specific delivery.

    Sources & context

    Waits and diagnostics: NHS England monthly statistics · ICB and provider data, not PCN

    Powered by Coplug · Page 8 of 15
    09 / 15

    Practice variation and patient experience

    Practice variation and patient experience

    GP Patient Survey by practice

    PracticeResponses% in IMD Q1Phone easyRequest led to apptOverall good
    Village Medical1035.788.9%49.4%90.6%
    Speke Hc - Dr9695.969.3%79.7%88.2%
    The Ash Surgery1141.963.8%77.6%85.8%
    Grassendale1055.269.8%72.8%85.5%
    Hillfoot Health11025.265.4%75.4%85.3%
    Mather Avenue10418.569.5%69.3%84.8%
    Village10048.757.6%66.9%84.4%
    Woolton House1136.839.2%76.1%82.7%
    Storrsdale1060.070.9%65.6%81.6%
    Gateacre9656.657.8%68.4%81.5%
    Margaret Thompson10585.055.3%70.7%79.7%
    Fulwood Green1210.072.1%66.4%79.2%
    Speke Hc - Dr8797.378.6%76.3%76.0%
    Garston Family9859.059.1%71.8%75.9%
    Gateacre Brow12027.025.5%67.4%64.6%
    Netherley89100.018.4%58.5%34.7%
    England—~2156.9%71.6%76.7%
    Sources & context

    QOF achievement; GP Patient Survey, practice-level results

    Powered by Coplug · Page 9 of 15
    11 / 15

    What the data can't tell us: gaps and local assets

    What the data can't tell us: gaps and local assets

    Local assets and voluntary sectorPCNLiverpool (LAD)AssetPCNLiverpool (LAD)
    Care homes (catchment)25 (1,099 beds)n/aSchools (catchment)122n/a
    Children's centres626Places of worship40240
    Libraries417Homelessness support (VCS)n/a1
    Primary schools (LA maintained)2291Primary academies620
    Special schools28

    0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.

    Sources & context

    Gaps are modelled estimates against benchmark rates; local assets as supplied

    Powered by Coplug · Page 11 of 15
    12 / 15

    Options for the PCN

    Options for the PCN

    Each option in full

    Option 1

    Structured asthma review recall

    Asthma review coverage is 63.8% (Liverpool (LAD) 64.3%, ICB 62.3%, England 65.7%) with 3-year growth of +0.1% (England +4.4%), leaving about 2,200 of 6,172 register patients unreviewed. For discussion, practices could run a single-template asthma recall prioritising high-deprivation lists and combining inhaler checks with flexible review slots. Moderate effort to run.

    Evidence base: the annual asthma review is the process gap between the register and outcomes.

    Policy anchor: Core20PLUS5 chronic respiratory disease priority.

    Option 2

    Hypertension and lipid therapy recall

    Across 16,777 hypertension patients (17.8% vs England 15.2%), recent BP recording is 86.0% (Liverpool (LAD) 87.8%, ICB 88.3%, England 90.0%) and QRISK >= 20% lipid therapy is 61.8% (England 63.6%). Moderate effort to run.

    Evidence base: the hypertension register is the cohort for case-finding, blood-pressure control and AF anticoagulation; its size and growth set the workload those interventions must cover, and a shortfall in control shows up later as emergency admission.

    Policy anchor: Core20PLUS5 (hypertension case-finding and optimal management); NHS CVD ambitions to 2029 on detection, treatment to target and statins for high-risk patients (CVDPREVENT).

    Option 3

    Age-five pre-school immunisation recall

    In Q1 2025/26 (cohort 207), age-5 4-in-1 coverage is 82.1% (ICB 82.9%, England 80.9%), 12.9 pp below the 95.0% target, and MMR2 is 81.2% (8.2 pp below MMR1 at 89.4%). For discussion, practices could audit children approaching age five for missing MMR2 and 4-in-1 boosters and offer combined catch-up slots. Low cost, quick to run.

    Evidence base: coverage against the 95% target is the direct measure of programme delivery and catch-up need; where coverage clusters low, that decides whether catch-up is organised at practice, PCN, school or outreach level.

    Policy anchor: 10 Year Health Plan, shift from sickness to prevention.

    Sources & context

    Options are the profile's; evidence base from Coplug's indicator catalogue

    Powered by Coplug · Page 12 of 15
    13 / 15

    Provenance and audit trail

    Provenance and audit trail

    Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.

    RecommendationIndicator(s)Policy anchorData level
    Older adult capacity planning (p2)Aged 65+Neighbourhood health framework · NHS vaccination strategyPCN
    Targeted Core20 clinical review outreach (p3)Core20 cohort (IMD quintile 1)Core20PLUS5 · 10YHP equity testPCN
    SMI physical health checks (p4)SMI register with a BP check in the last 12 monthsMHIS · From Harm to HopePCN
    Hypertension recall and monitoring (p5)Last BP reading of patients (<80 yrs with hypertension) in the last 12 months is <= 140/90 mmHg (denominator incl. PCAs)Core20PLUS5 CVD · CVDPREVENT 2029PCN
    Pre-school immunisation call-recall (p6)MMR dose 2 coverage at age 510YHP sickness to prevention · 95% targetPCN
    Screening uptake audit (p7)Women (25-49 yrs) with a record of cervical screening in the last 3.5 yrs (denominator incl. PCAs)Fit for the Future: 10 Year Health Plan for England · Medium Term Planning Framework 2026PCN
    Option 1 · Structured asthma review recall (p12)Asthma register · Asthma: QOF prevalence · Patients with Asthma: review in the last 12 months (denominator incl. PCAs)Core20PLUS5 respiratoryPCN
    Option 2 · Hypertension and lipid therapy recall (p12)Registered population · Hypertension register · Hypertension: QOF prevalenceCore20PLUS5 CVD · CVDPREVENT 2029PCN
    Option 3 · Age-five pre-school immunisation recall (p12)4-in-1 pre-school booster (DTaP/IPV) coverage at age 5 · MMR dose 1 coverage at age 5 · MMR dose 2 coverage at age 510YHP sickness to prevention · 95% targetPCN
    Sources & context

    Re-run this profile in 12 months to see whether the gaps have narrowed

    Powered by Coplug · Page 13 of 15
    14 / 15

    Data sources

    Data sources

    Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.

    DatasetLevelPeriodUsed for
    Coplug indicator tables: census, deprivation and QOF measuresPCN & Practice2023 to 2025, projected to 2030; 2023 to 2024Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12
    MHCLG, Rough sleeping snapshot in England: autumn 2025Local authorityAutumn 2025Pages 2, 4
    OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713)PCN2024/25Pages 2, 4
    OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002)Local authority2024/25; 2022-24Pages 2, 4
    ONS, Census 2021 TS039: provision of unpaid care (age-standardised)Local authorityCensus 2021Pages 2, 4
    QOF registers, prevalence and care processes (Coplug indicator tables)Practice2023 to 2025, projected to 2030Pages 4, 5, 6, 7, 8, 10
    UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26PCN & PracticeQ1 2025/26Pages 4, 6
    UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026Local authority2025/26 season to 28 Feb 2026Pages 4, 6
    NHS England, Cancer Waiting Times: July 2026 monthly time series with revisionsICB & ProviderJul 2026 (provisional)Pages 7, 8
    NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental dataICB & Local authorityJun 2026 (provisional)Pages 7, 8
    NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026ProviderJul 2026Pages 7, 8
    National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022ICB2022Pages 7, 8
    NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted)PracticeSurvey Jan-Apr 2026Page 9
    NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domainPractice2025/26Page 9
    NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domainPractice2025/26Page 9
    Coplug indicator catalogue — definitions, cohorts, policy anchorsReferenceCurrentEvidence-base lines, page 13
    Sources & context

    Where a period is given as "as supplied", the source file did not state a vintage

    Powered by Coplug · Page 14 of 15
    15 / 15

    Methods, data-quality notes and limitations

    Methods, data-quality notes and limitations

    Methods

    Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.

    Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.

    Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.

    Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.

    Sources & context

    Estimates size the task; they are not confirmed missed patients

    Powered by Coplug · Page 15 of 15